Long-acting Melatonin Receptor Agonists Market Report – Research, Industry Analysis Reports and Market Demands

Global Long-acting Melatonin Receptor Agonists Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

2 Company Profiles

3 Market Competition, by Players

3.1 Global Long-acting Melatonin Receptor Agonists Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of Long-acting Melatonin Receptor Agonists by Company Revenue
- 3.2.2 Top 3 Long-acting Melatonin Receptor Agonists Players Market Share in 2025
- 3.2.3 Top 6 Long-acting Melatonin Receptor Agonists Players Market Share in 2025
3.3 Long-acting Melatonin Receptor Agonists Market: Overall Company Footprint Analysis
- 3.3.1 Long-acting Melatonin Receptor Agonists Market: Region Footprint
- 3.3.2 Long-acting Melatonin Receptor Agonists Market: Company Product Type Footprint
- 3.3.3 Long-acting Melatonin Receptor Agonists Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

4.1 Global Long-acting Melatonin Receptor Agonists Consumption Value and Market Share by Type (2021-2026)
4.2 Global Long-acting Melatonin Receptor Agonists Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

5.1 Global Long-acting Melatonin Receptor Agonists Consumption Value Market Share by Application (2021-2026)
5.2 Global Long-acting Melatonin Receptor Agonists Market Forecast by Application (2027-2032)

6 North America

6.1 North America Long-acting Melatonin Receptor Agonists Consumption Value by Type (2021-2032)
6.2 North America Long-acting Melatonin Receptor Agonists Market Size by Application (2021-2032)
6.3 North America Long-acting Melatonin Receptor Agonists Market Size by Country
- 6.3.1 North America Long-acting Melatonin Receptor Agonists Consumption Value by Country (2021-2032)
- 6.3.2 United States Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)
- 6.3.3 Canada Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)
- 6.3.4 Mexico Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)

7 Europe

7.1 Europe Long-acting Melatonin Receptor Agonists Consumption Value by Type (2021-2032)
7.2 Europe Long-acting Melatonin Receptor Agonists Consumption Value by Application (2021-2032)
7.3 Europe Long-acting Melatonin Receptor Agonists Market Size by Country
- 7.3.1 Europe Long-acting Melatonin Receptor Agonists Consumption Value by Country (2021-2032)
- 7.3.2 Germany Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)
- 7.3.3 France Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)
- 7.3.5 Russia Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)
- 7.3.6 Italy Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)

8 Asia-Pacific

8.1 Asia-Pacific Long-acting Melatonin Receptor Agonists Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Long-acting Melatonin Receptor Agonists Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Long-acting Melatonin Receptor Agonists Market Size by Region
- 8.3.1 Asia-Pacific Long-acting Melatonin Receptor Agonists Consumption Value by Region (2021-2032)
- 8.3.2 China Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)
- 8.3.3 Japan Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)
- 8.3.4 South Korea Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)
- 8.3.5 India Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)
- 8.3.7 Australia Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)

9 South America

9.1 South America Long-acting Melatonin Receptor Agonists Consumption Value by Type (2021-2032)
9.2 South America Long-acting Melatonin Receptor Agonists Consumption Value by Application (2021-2032)
9.3 South America Long-acting Melatonin Receptor Agonists Market Size by Country
- 9.3.1 South America Long-acting Melatonin Receptor Agonists Consumption Value by Country (2021-2032)
- 9.3.2 Brazil Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)
- 9.3.3 Argentina Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)

10 Middle East & Africa

10.1 Middle East & Africa Long-acting Melatonin Receptor Agonists Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Long-acting Melatonin Receptor Agonists Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Long-acting Melatonin Receptor Agonists Market Size by Country
- 10.3.1 Middle East & Africa Long-acting Melatonin Receptor Agonists Consumption Value by Country (2021-2032)
- 10.3.2 Turkey Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)
- 10.3.4 UAE Long-acting Melatonin Receptor Agonists Market Size and Forecast (2021-2032)

11 Market Dynamics

11.1 Long-acting Melatonin Receptor Agonists Market Drivers
11.2 Long-acting Melatonin Receptor Agonists Market Restraints
11.3 Long-acting Melatonin Receptor Agonists Trends Analysis
11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

12.1 Long-acting Melatonin Receptor Agonists Industry Chain
12.2 Long-acting Melatonin Receptor Agonists Upstream Analysis
12.3 Long-acting Melatonin Receptor Agonists Midstream Analysis
12.4 Long-acting Melatonin Receptor Agonists Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology
14.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Long-acting Melatonin Receptor Agonists market size was valued at US$ 475 million in 2025 and is forecast to a readjusted size of US$ 723 million by 2032 with a CAGR of 6.1% during review period.
Long-acting melatonin receptor agonists are prescription medicines containing melatonin and formulated with prolonged-release, extended-release, or controlled-release technologies to extend overnight drug release and MT1 and MT2 receptor activity. Commercial products mainly include 2 mg prolonged-release tablets for adults and 1 mg or 5 mg prolonged-release minitablets for pediatric patients. Major indications include primary insomnia and insomnia associated with autism spectrum disorder, Smith-Magenis syndrome, other neurogenetic disorders, and selected pediatric attention-deficit hyperactivity disorder populations. Upstream inputs mainly include pharmaceutical-grade melatonin, modified-release matrix materials, methacrylate copolymers, cellulose derivatives, fillers, coating materials, blister packs, and pharmaceutical bottles. Downstream customers mainly include sleep medicine centers, psychiatric departments, pediatric departments, neurodevelopmental disorder clinics, hospital pharmacies, retail pharmacies, and specialty pharmacies. The market is centered on prescription prolonged-release formulations. Originator pediatric products retain relatively high added value, while adult 2 mg prolonged-release tablets face increasing generic competition, with an overall gross margin generally ranging from approximately 48% to 72%.
From the current market perspective, the long-acting melatonin receptor agonist market consists mainly of adult 2 mg prolonged-release melatonin products and pediatric prolonged-release formulations. The adult segment is concentrated in primary insomnia among older patients and includes both originator and generic products. Pediatric products primarily address insomnia associated with autism spectrum disorder, neurogenetic diseases, and other neurodevelopmental disorders. These populations are smaller but require more specialized diagnosis and treatment, supporting higher unit values for branded pediatric formulations.
Looking ahead, development will increasingly focus on pediatric dosage forms, minitablets, easy-to-swallow formulations, and more consistent overnight release profiles. Manufacturers will optimize release rates, overnight exposure, morning residual effects, and dosing for different age and weight groups. Generic penetration will continue to increase in the adult 2 mg segment, while pediatric products will rely more heavily on proprietary formulations, indication expansion, and specialist promotion.
Key market drivers include population aging, increasing recognition of sleep disorders, improved diagnosis of pediatric neurodevelopmental conditions, and greater physician acceptance of non-GABAergic insomnia treatments. These products are generally not controlled substances and have lower abuse and physical-dependence risks than benzodiazepines and Z-drugs, making them suitable for patients requiring longer treatment or unable to tolerate conventional sedative-hypnotics. Expansion into autism, ADHD, and neurogenetic disorder-related insomnia will create additional prescription demand.
The main constraints include relatively modest clinical efficacy in some patients and variable improvement in sleep onset and maintenance. Low-priced and widely available over-the-counter immediate-release melatonin products create substantial substitution pressure. Regulatory classification of melatonin as a medicine, food, or dietary supplement differs by country, resulting in inconsistent reimbursement, prescribing, and market-access conditions. Generic competition and reimbursement controls will also continue to reduce average selling prices in the adult segment.
This report is a detailed and comprehensive analysis for global Long-acting Melatonin Receptor Agonists market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Long-acting Melatonin Receptor Agonists market size and forecasts, in consumption value ($ Million), 2021-2032
Global Long-acting Melatonin Receptor Agonists market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Long-acting Melatonin Receptor Agonists market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Long-acting Melatonin Receptor Agonists market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Long-acting Melatonin Receptor Agonists
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Long-acting Melatonin Receptor Agonists market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Neurim Pharmaceuticals, Flynn Pharma, Viatris, Teva Pharmaceutical Industries, Aurobindo Pharma, Sandoz, Zentiva, Neuraxpharm, Wockhardt, Medice, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Long-acting Melatonin Receptor Agonists market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
1 mg
2 mg
5 mg
Other
Market segment by Product Status
Originator Drug
Generic Drugs
Market segment by Release Profile
Prolonged-release
Extended-release
Modified-release
Market segment by Application
Hospital
Clinic
Other
Market segment by players, this report covers
Neurim Pharmaceuticals
Flynn Pharma
Viatris
Teva Pharmaceutical Industries
Aurobindo Pharma
Sandoz
Zentiva
Neuraxpharm
Wockhardt
Medice
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Long-acting Melatonin Receptor Agonists product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Long-acting Melatonin Receptor Agonists, with revenue, gross margin, and global market share of Long-acting Melatonin Receptor Agonists from 2021 to 2026.
Chapter 3, the Long-acting Melatonin Receptor Agonists competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Long-acting Melatonin Receptor Agonists market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Long-acting Melatonin Receptor Agonists.
Chapter 13, to describe Long-acting Melatonin Receptor Agonists research findings and conclusion.

Buy now